Adis JournalsBrowse
summary slide.png (128.67 kB)
Download file

Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results From a Phase 2 Open-Label Extension Trial

Download (128.67 kB)
media
posted on 26.01.2021, 16:59 authored by Adis journals on behalf of, Kim A. Papp, Saskia de Vente, Jiewei Zeng, Mary Flack, Byron Padilla, Stephen K. Tyring

Article full text


The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).

© The authors, CC-BY-NC 2021.

History

References

Usage metrics

Read the peer-reviewed publication

Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results From a Phase 2 Open-Label Extension Trial
Dermatology and TherapyDermatology and Therapy

Categories

Keywords

Biologic therapyInterleukin-23Open-label extensionPsoriasisRisankizumab

Licence

CC BY-NC 4.0

Exports